KALA BIO, Inc. Common Stock (KALA) Stock Price

KALAStock

$0.69−99.87%52W

Market Cap$13.35M

P/E—

PEG Ratio—

Div yield—

Beta-2.63

KALA Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-108.57%

Price vs S&P 500 (4W)-13.41%

VGM Score30.08

Book Value / Share (Quarterly)$44.23

P/TBV (Annual)0.88x

Indicated Dividend (Annual)$0.00

Cash Flow / Share (Quarterly)$-216.04

Price vs S&P 500 (YTD)-110.34%

Gross Margin (TTM)30.96%

Net Profit Margin (TTM)-1383.48%

EPS (TTM)$-136.77

10-Day Avg Trading Volume0.29M

EPS Excl Extra (TTM)$-136.77

EPS (Annual)$-10.26

ROI (Annual)-91.19%

Gross Margin (Annual)34.19%

Net Profit Margin (5Y Avg)-7795.15%

Cash / Share (Quarterly)$141.91

ROA (Last FY)-70.29%

EBITD / Share (TTM)$-7.82

ROE (5Y Avg)-413.54%

Operating Margin (TTM)-1261.57%

Cash Flow / Share (Annual)$-242.90

P/B Ratio3.12x

P/B Ratio (Quarterly)6.48x

Net Income / Employee (Annual)$-6,500,000

EV / Revenue (TTM)4.37x

Net Interest Coverage (TTM)-12.60x

ROA (TTM)-86.99%

EPS Incl Extra (Annual)$-10.26

Current Ratio (Annual)3.11x

Quick Ratio (Quarterly)0.65x

3-Month Avg Trading Volume0.14M

52-Week Price Return-99.87%

Revenue / Employee (TTM)$0

Tangible BV / Share (Quarterly)$4.17

P/S Ratio (Annual)4.57x

Asset Turnover (Annual)0.04x

52-Week High$1030.00

Operating Margin (5Y Avg)-7404.03%

EPS Excl Extra (Annual)$-10.26

CapEx CAGR (5Y)-62.19%

Tangible BV CAGR (5Y)-26.70%

26-Week Price Return-96.64%

Quick Ratio (Annual)3.02x

13-Week Price Return-69.86%

Total Debt / Equity (Annual)2.47x

Current Ratio (Quarterly)0.75x

Enterprise Value$25.10M

Asset Turnover (TTM)0.05x

Book Value / Share Growth (5Y)19.00%

Revenue / Employee (Annual)$0

Inventory Turnover (Annual)0.60x

Pretax Margin (Annual)-1152.19%

Cash / Share (Annual)$420.14

3-Month Return Std Dev131.44%

Net Income / Employee (TTM)$-3,275,700

ROE (Last FY)-316.25%

Net Interest Coverage (Annual)-11.63x

EPS Basic Excl Extra (Annual)$-10.26

Receivables Turnover (TTM)0.00x

Total Debt / Equity (Quarterly)5.37x

EPS Incl Extra (TTM)$-136.77

Receivables Turnover (Annual)0.00x

ROI (TTM)-83.84%

P/S Ratio (TTM)3.09x

Pretax Margin (5Y Avg)-7795.15%

Revenue / Share (Annual)$0.00

Tangible BV / Share (Annual)$11.12

Price vs S&P 500 (52W)-118.43%

Year-to-Date Return-97.52%

5-Day Price Return-13.24%

EPS Normalized (Annual)$-10.26

ROA (5Y Avg)-69.35%

Net Profit Margin (Annual)-1152.19%

Month-to-Date Return-8.70%

Cash Flow / Share (TTM)$-21.40

EBITD / Share (Annual)$-10.72

Operating Margin (Annual)-958.61%

LT Debt / Equity (Annual)1.63x

ROI (5Y Avg)-94.88%

LT Debt / Equity (Quarterly)2.65x

EPS Basic Excl Extra (TTM)$-136.77

P/TBV (Quarterly)1.49x

P/B Ratio (Annual)3.43x

Inventory Turnover (TTM)0.60x

Pretax Margin (TTM)-1383.48%

Book Value / Share (Annual)$101.23

Price vs S&P 500 (13W)-71.82%

Beta-2.63x

Revenue / Share (TTM)$0.00

ROE (TTM)-366.61%

52-Week Low$0.59

vGradeC

mGradeF

vgmGradeD

KALA Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q3 2025	Nov 19, 2025	-$50.50	-$53.50	-5.94%(-$3.00)
Q2 2025	Aug 8, 2025	-$102.00	-$65.94	+35.36%(+$36.06)
Q1 2025	May 14, 2025	-$127.00	-$50.66	+60.11%(+$76.34)
Q4 2024	Mar 31, 2025	-$123.50	-$61.58	+50.14%(+$61.92)

KALA Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

2.17

Industry Peers — Pharmaceuticals(570)

Symbol	Value Score	Growth Score	Momentum Score	Price
KALAKALA BIO, Inc. Common Stock	C	—	F	$0.69
LLYEli Lilly & Co.	D	B	C	$1174.61
JNJJohnson & Johnson	D	C	B	$268.04
ABBVABBVIE INC.	D	C	B	$255.48
MRKMerck & Co., Inc.	D	C	B	$148.35
NVSNovartis AG	C	C	C	$153.81
AZNAstraZeneca PLC	C	B	C	$162.70
NVONovo-Nordisk A/S	B	C	C	$45.61
ABTAbbott Laboratories	C	C	C	$112.47
PFEPfizer Inc.	C	D	B	$27.96
VRTXVertex Pharmaceuticals Inc	D	C	B	$541.69
BMYBristol-Myers Squibb Co.	B	B	B	$66.58
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	C	C	$44.82
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	B	C	C	$50.82
REGNRegeneron Pharmaceuticals Inc	C	C	B	$794.19
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	B	$18.03
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$36.44
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	B	$366.73
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	B	$60.85
ZTSZOETIS INC.	C	C	D	$77.34
ALNYAlnylam Pharmaceuticals, Inc.	D	A	D	$237.10
INSMInsmed, Inc.	F	A	C	$118.54
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	$34.71
UTHRUnited Therapeutics Corp	C	C	B	$515.46
GMABGenmab A/S ADS	C	C	B	$33.23
VTRSViatris Inc. Common Stock	B	C	B	$16.34
ASNDAscendis Pharma A/S Ordinary Share	D	A	C	$247.91
JAZZJazz Pharmaceuticals, Inc.	B	C	B	$244.54
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	$76.60
BMRNBioMarin Pharmaceuticals Inc	C	C	B	$64.67
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	B	$533.76
CORTCorcept Therapeutics Inc.	F	C	B	$113.88
ELANElanco Animal Health Incorporated Common Stock	C	B	C	$24.11
ARWRArrowhead Research Corporation	D	A	B	$84.91
SMMTSummit Therapeutics Inc. Common Stock	F	—	D	$13.73
AXSMAxsome Therapeutics, Inc	D	B	C	$199.02
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	D	C	$12.18
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	$61.05
CYTKCytokinetics Inc.	F	D	C	$72.09
ABVXAbivax SA American Depositary Shares	—	—	C	$113.35
NUVLNuvalent, Inc. Class A Common Stock	—	—	B	$123.96
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	$344.75
PTGXProtagonist Therapeutics, Inc	F	B	B	$144.33
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	$84.84
TGTXTG Therapeutics, Inc.	D	B	B	$53.93
SYRESpyre Therapeutics, Inc. Common Stock	—	—	B	$90.36
ALKSAlkermes Inc. plc	D	C	B	$47.41
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	$107.17
ERASErasca, Inc. Common Stock	—	—	A	$18.03
TVTXTravere Therapeutics, Inc. Common Stock	F	B	A	$65.67
BLTEBelite Bio, Inc American Depositary Shares	—	—	C	$151.72

About KALA BIO, Inc. Common Stock

Kala Bio is a clinical-stage biopharmaceutical company developing cell-derived therapies for rare eye diseases. The company's lead candidate, KPI-012, is a human mesenchymal stem cell product designed to restore corneal healing and treat severe retinal degenerative diseases including Retinitis Pigmentosa and Stargardt Disease. KPI-012 leverages multiple therapeutic factors including growth factors and neuroprotective proteins to address unmet needs in vision-threatening conditions.